Table 3.
The results of reference interval validation in 5 laboratories
Analytes | Age group (y) | Sex group | Reference intervals | N a | Lab 1 | Lab 2 | Lab 3 | Lab 4 | Lab 5 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n b | Result, %c | n b | Result, %c | n b | Result, %c | n b | Result, %c | n b | Result, %c | |||||
ALT (U/L) | 2 | F + M | 8–24 | 20 | 2 | 90 | 1 | 95 | 1 | 95 | 1 | 95 | 1 | 95 |
3 to < 6 | F + M | 7–23 | 20 | 2 | 90 | 2 | 90 | 2 | 90 | 2 | 90 | 1 | 95 | |
7 to < 10 | F + M | 4–19 | 20 | 2 | 90 | 2 | 90 | 2 | 90 | 2 | 90 | 0 | 100 | |
11 to < 14 | F | 5–25 | 20 | 1 | 95 | 0 | 100 | 2 | 90 | 2 | 90 | 0 | 100 | |
M | 5–35 | 20 | 1 | 95 | 0 | 100 | 0 | 100 | 0 | 100 | 1 | 95 | ||
AST (U/L) | 2 | F + M | 27–49 | 20 | 2 | 90 | 2 | 90 | 1 | 95 | 2 | 90 | 2 | 90 |
3 to < 5 | F + M | 22–44 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 1 | 95 | |
6 | F + M | 18–40 | 20 | 0 | 100 | 1 | 95 | 0 | 100 | 0 | 100 | 0 | 100 | |
7 to < 12 | F | 11–35 | 20 | 1 | 95 | 2 | 90 | 0 | 100 | 1 | 95 | 1 | 95 | |
M | 13–39 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 0 | 100 | ||
13 to < 14 | F | 14–26 | 20 | 1 | 95 | 2 | 90 | 2 | 90 | 2 | 90 | 0 | 100 | |
M | 13–36 | 20 | 1 | 95 | 1 | 95 | 0 | 100 | 2 | 90 | 1 | 95 | ||
GGT (U/L) | 2 to < 4 | F + M | 8–16 | 20 | 0 | 100 | 0 | 100 | 0 | 100 | 2 | 90 | 2 | 90 |
5 to < 10 | F + M | 8–21 | 20 | 1 | 95 | 0 | 100 | 0 | 100 | 2 | 90 | 1 | 95 | |
11 to < 14 | F | 8–29 | 20 | 0 | 100 | 2 | 90 | 2 | 90 | 2 | 90 | 0 | 100 | |
M | 10–43 | 20 | 1 | 95 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | ||
ALP (U/L) | 2 to < 3 | F + M | 160–376 | 20 | 2 | 90 | 2 | 90 | 2 | 90 | 2 | 90 | 0 | 100 |
4 to < 9 | F + M | 143–362 | 20 | 1 | 95 | 2 | 90 | 0 | 100 | 1 | 95 | 0 | 100 | |
10 to < 12 | F + M | 116–426 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 2 | 90 | |
13 to < 14 | F | 48–232 | 20 | 1 | 95 | 1 | 95 | 2 | 90 | 2 | 90 | 2 | 90 | |
M | 111–486 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 2 | 90 | ||
TP (g/L) | 2 to < 3 | F + M | 59.5–74.4 | 20 | 1 | 95 | 2 | 90 | 0 | 95 | 2 | 90 | 1 | 95 |
4 to < 6 | F + M | 59.2–76.4 | 20 | 0 | 100 | 1 | 95 | 0 | 100 | 2 | 90 | 0 | 100 | |
7 to < 10 | F + M | 62.5–78.2 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 1 | 95 | |
11 to < 14 | F + M | 63.6–79.2 | 20 | 0 | 100 | 1 | 95 | 0 | 100 | 2 | 90 | 2 | 90 | |
ALB (g/L) | 2 to < 10 | F + M | 40.0–52.3 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 0 | 100 |
11 to < 14 | F + M | 41.3–53.1 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 0 | 100 | |
TBIL | 2 to < 3 | F + M | 3.00–13.01 | 20 | 0 | 100 | 1 | 95 | 1 | 95 | 2 | 90 | 0 | 100 |
(µmol/L) | 4 to < 7 | F + M | 3.41–14.80 | 20 | 0 | 100 | 1 | 95 | 0 | 100 | 1 | 95 | 0 | 100 |
8 to < 14 | F + M | 4.50–16.60 | 20 | 0 | 100 | 2 | 90 | 0 | 100 | 2 | 90 | 1 | 95 | |
DBIL | 2 to < 3 | F + M | 0.90–3.30 | 20 | 0 | 100 | 1 | 95 | 2 | 90 | 2 | 90 | 0 | 100 |
(µmol/L) | 4 to < 7 | F + M | 1.10–3.80 | 20 | 0 | 100 | 2 | 90 | 1 | 95 | 2 | 90 | 0 | 100 |
8 to < 12 | F + M | 1.60–4.50 | 20 | 2 | 90 | 2 | 90 | 2 | 90 | 2 | 90 | 2 | 90 | |
13 to < 14 | F + M | 1.20–5.30 | 20 | 1 | 95 | 2 | 90 | 1 | 95 | 2 | 90 | 0 | 100 |
ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyltransferase, ALP alkaline phosphatase, TP total protein, ALB albumin, TBIL total bilirubin, DBIL direct bilirubin, M male, F female. aNumber for validation samples of this study. bNumber for validation samples outside the reference intervals of this study. cThe results of percentage of validation samples inside the reference intervals of this study